SCHEMBL1617387

SCHEMBL1617387

CN(C)/C=C1/CCCC(O)C1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.35
KDM4E B2RXH2 3/20 0.35
HSD17B10 Q99714 3/20 0.35
ALDH1A1 P00352 3/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 2/20 0.35
RAB9A P51151 2/20 0.35
HPGD P15428 2/20 0.35
THRB P10828 1/20 0.35
ALOX12 P18054 1/20 0.35
CASP1 P29466 1/20 0.35
RECQL P46063 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTT P42858 2/20 0.33
LMNA P02545 1/20 0.33
CYP2C9 P11712 1/20 0.33
ALOX15 P16050 1/20 0.33
CYP2C19 P33261 1/20 0.33
CREBBP Q92793 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1617390 1.00 MAPT (0.35) MAPTKDM4EHSD17B10ALDH1A1MEN1
SCHEMBL1616963 0.75 LMNA (0.32) MAPTHSD17B10HTTLMNACYP2C9
SCHEMBL1617565 0.75 NPC1 (0.42) MAPTKDM4EHSD17B10ALDH1A1MEN1
SCHEMBL21014711 0.74 TP53 (0.34) MAPTHSD17B10L3MBTL1HTTLMNA
SCHEMBL23276726 0.74 MAPT (0.42) MAPTKDM4EHSD17B10ALDH1A1MEN1
SCHEMBL23276727 0.74 MAPT (0.42) MAPTKDM4EHSD17B10ALDH1A1MEN1
SCHEMBL1616973 0.72 L3MBTL1 (0.38) MAPTHSD17B10HPGDL3MBTL1HTT
SCHEMBL1616974 0.72 L3MBTL1 (0.38) MAPTHSD17B10HPGDL3MBTL1HTT
SCHEMBL1617059 0.71 AKR1C3 (0.38) MAPTALDH1A1RAB9ANPC1
SCHEMBL1617057 0.71 AKR1C3 (0.38) MAPTALDH1A1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012030952-A3 REDUCING RIPPLE CURRENT IN A SWITCHED-MODE POWER CONVERTER EMPLOYING A BRIDGE TOPOLOGY TEXAS INSTRUMENTS INCORPORATED (US) 2012-05-10 WO disclosed
EP-2231629-B1 MODULATORS FOR AMYLOID BETA HOFFMANN LA ROCHE (CH) 2011-11-30 EP disclosed
US-7923450-B2 Modulators for amyloid beta HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
EP-2231629-A1 MODULATORS FOR AMYLOID BETA F. Hoffmann-La Roche AG (CH) 2010-09-29 EP disclosed
WO-2009087127-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 WO disclosed
US-20090181965-A1 MODULATORS FOR AMYLOID BETA F. HOFFMANN-LA ROCHE AG (CH) 2009-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181965-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, BACE1 MAPT 26/4885KDM4E 4361/4885HSD17B10 1059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.